Company Overview
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Why Investors Should Care
Revenue has grown at a 16.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $201.49M (+0.5% YoY); net profit $-66.54M.
- Trailing 12 Months Year-on-year growth — revenue +6.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.76% |
| 1 Year: | 6.50% |
Stock Price Performance
| 1 Year: | +37.91% |
| 6 Months: | -15.23% |
| 3 Months: | +0.65% |
| 1 Month: | +14.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.8% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTKB Cytek Biosciences, Inc. R2K | 4.62 | -7.97 | $596.64M | 0.00% | -10.52% | -20.93% | 16.76% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 19.14M | 25.10M | 24.27M | 30.41M | 34.38M | 35.06M | 40.16M | 40.48M | 37.09M | 49.69M | 48.00M | 44.86M | 46.62M | 51.50M | 41.46M | 45.60M | 52.29M | 44.13M |
| Gross Profit | - | 8.27M | 15.62M | 14.49M | 19.75M | 21.28M | 20.18M | 24.56M | 26.86M | 21.04M | 28.16M | 27.18M | 23.01M | 25.44M | 29.00M | 20.16M | 23.87M | 27.55M | 21.25M |
| Operating Income | - | -218.00K | 6.71M | 1.13M | 3.81M | 2.90M | -2.36M | -891.00K | 1.36M | -12.16M | -9.13M | -6.42M | -10.73M | -8.53M | -4.25M | -14.97M | -10.62M | -9.19M | -18.46M |
| Net Income | -839.00K | 8.11M | 6.54M | 102.00K | 2.67M | 1.42M | -2.16M | -702.00K | 1.63M | -6.81M | -4.39M | - | -6.17M | - | - | -11.40M | - | - | -18.87M |
| Diluted EPS | - | 0.06 | 0.05 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | -0.01 | - | - | - | - | - | - | - | - | - | - |
| R&D Expense | - | 2.92M | 3.38M | 5.09M | 6.19M | 6.08M | 8.03M | 8.44M | 8.65M | 9.97M | 12.14M | 11.17M | 9.80M | 10.00M | 9.88M | 9.72M | 8.83M | 8.96M | 9.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 92.84M | 127.95M | 164.04M | 193.01M | 200.45M | 201.49M |
| Gross Profit | 51.71M | 79.14M | 100.97M | 109.43M | 111.11M | 104.46M |
| Operating Income | 13.66M | 9.16M | -1.80M | -27.84M | -20.52M | -40.38M |
| Net Income | 19.41M | 3.03M | 2.48M | -12.15M | -6.02M | -66.54M |
| Diluted EPS | 0.10 | 0.00 | 0.02 | -0.09 | - | - |
| R&D Expense | 13.69M | 24.44M | 34.86M | 44.15M | 39.40M | 36.47M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 219.98M | 463.31M | 519.48M | 494.46M | 499.50M | 461.54M |
| Total Equity | 41.70M | -16.03M | 405.38M | 425.55M | 393.06M | 395.74M | 341.74M |
| Cash & Equivalents | - | 165.23M | 364.62M | 296.60M | 167.30M | 98.72M | 90.85M |
| Total Liabilities | - | 41.69M | 57.92M | 93.93M | 101.39M | 103.76M | 119.80M |
| Current Liabilities | - | 26.54M | 33.18M | 49.04M | 56.23M | 67.66M | 77.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 15.16M | 4.63M | -12.23M | 5.28M | 25.38M | -4.69M |
| Investing Cash Flow | -1.55M | -20.99M | -55.91M | -93.89M | -82.97M | 10.12M |
| Financing Cash Flow | 122.61M | 213.56M | 5.51M | -41.81M | -15.82M | -13.43M |
| Capital Expenditure | -1.55M | -4.36M | -9.75M | -4.65M | -3.52M | -4.08M |
| Free Cash Flow | 13.61M | 266.00K | -21.98M | 633.00K | 21.85M | -8.77M |
| Share Buybacks | - | 0 | 0 | 44.15M | 21.61M | 15.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| Operating Margin % | 14.7% | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| Net Margin % | 20.9% | 2.4% | 1.5% | -6.3% | -3.0% | -33.0% |
| ROE % | -121.1% | 0.7% | 0.6% | -3.1% | -1.5% | -19.5% |
| ROCE % | 7.1% | 2.1% | -0.4% | -6.4% | -4.8% | -10.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.17% | 17.01M | $77.64M |
| 2 | Topline Capital Management, LLC | 5.47% | 7.06M | $32.25M |
| 3 | HHLR Advisors, LTD | 5.15% | 6.66M | $30.39M |
| 4 | Millennium Management Llc | 4.87% | 6.29M | $28.72M |
| 5 | Boston Partners | 4.49% | 5.80M | $26.49M |
| 6 | Vanguard Capital Management LLC | 3.69% | 4.76M | $21.74M |
| 7 | State Street Corporation | 3.19% | 4.12M | $18.82M |
| 8 | Geode Capital Management, LLC | 2.19% | 2.83M | $12.94M |
| 9 | Dimensional Fund Advisors LP | 2.06% | 2.66M | $12.16M |
| 10 | Goldman Sachs Group Inc | 1.82% | 2.34M | $10.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTKB
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPclg1V0JvRHEtdzRwZmdRQjM3RURTakNrYnRYWk5nSk5QUW5GcU44b0M5UGdEN3YxcXh5cU43SElYWUo0RlJ4U2hQZUNxd0VVVjN6LTZ3YlBEeEI5SWtmRS15dWFpSUpjT2x2RFU5b2ZkcXdDXzU1VmRZRVVnSnRocmVCMGVWQ2xiOE1NdU…
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNSGpicmFNVmhrdzJPc1Bzam5BUW40MjQ0TkY2TEpkSC1zTTV4bFBaaWQyMU50Q0p1QXhFZWxrZWhBM1dPM05PU0Mxcmpjb053YTFrUDN4TmI0YXNibEJ6SkEwRGU5ZkVlOG4zWE5HWXBnSEdaTjRTQm9Ja0pOZTNDclFJUDF5ZUxKTEEwQT…
Cytek Biosciences Announces Chief Legal Officer Transition - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPempXWkQxRUQ4YzJXZlRCanh4cHI0U3FvWk94M1hxcEstZG9fTDZOWGRYTjVoSDkzYURKS3poSzhnWFo3dlcxR3hGQ01JYWFKTFBhd3RYMHFucmFzOFBYZ3VucFpRVlV1QVV1N05lVnF0UldsZjZwR000eEhmcnJ1UXVETXUxaFNaRWRUUD…
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPV29xN1NTc1RZVTlPRVRJcFc4c2pFZlRqampxVWdhakoxY1pGMm9Tc2wza3NyQ3BWOUVTSzhkQVV0TmQ5b3g4NlpXUXZnWk9zcEdrZHJwRjQtQUZjVGlsVzYyMkJYOFVlbElveXNDTWpQdDdCMGQ0X205QW9pVlh6QUtwd2xMT0d0YWkzdF…
Cytek Biosciences Reports First Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOSlZ5Wnd3d0J3MEVfM0NlN0xnQWtvbHZzZDRSdE0yQkJmak1yUUdCdkdsbXN3VG1ON2MwREc2ZWF1Vk5YclJZY1JfVHZ1WWdkenZiYmk0cVBvMVhiN3JoSURNN1liSHdMSkk3dGdTOGNFUUEyS2ZRWUpZelJkVjAtSVowSk9BZ1JST2YzZ1…
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500 - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPVlZSUVRpOGZ4M1Q1cWJ3cVdkcThtYXBKWURzenpwM3BlUmh5QjRGaE00WnpMUjV5VUEtN0hMVTNqQk9BdEdmLXhwZk9CVFZnWldSbHY1OFJfczFseHlIcVNnd3pzNTZhbHBWSzItLXFkUE5LV081U3Zwak5TQ2pzeWdObWtfdE9vRHZFSV…
CTKB — Frequently Asked Questions
What is the current share price of Cytek Biosciences, Inc. (CTKB)?
As of 2026-07-14 21:23 PDT, Cytek Biosciences, Inc. (CTKB) trades at $4.62 on NasdaqGS. Its 52-week range is $3.10 to $5.88.
What is the market capitalisation of CTKB?
Cytek Biosciences, Inc. (CTKB) has a market capitalisation of $596.64M on NasdaqGS.
What is the P/E ratio of CTKB?
CTKB trades at a trailing price-to-earnings (P/E) ratio of -7.97. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.56.
What is the return on equity (ROE) of CTKB?
CTKB has a return on equity (ROE) of -20.93%. Its return on capital employed (ROCE) is -10.52%.
Is CTKB a good stock to buy?
This page provides a data-driven analysis of Cytek Biosciences, Inc. (CTKB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.